Zongertinib

Cat. No.: HY-148810

CAS No.: 2728667-27-2

Molecular Formula: $C_{29}H_{29}N_9O_2$

Molecular Weight: 535.6

Target: c-Met/HGFR

Pathway: Protein Tyrosine Kinase/RTK

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 31.25 mg/mL (58.35 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.8671 mL	9.3353 mL	18.6707 mL
	5 mM	0.3734 mL	1.8671 mL	3.7341 mL
	10 mM	0.1867 mL	0.9335 mL	1.8671 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (4.67 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC_{50} values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors[1][2][3].

In Vitro

Zongertinib in NCI-H-2170 HER2 wt amp, NCI-H2170 HER2 YVMA, A431 EGFR wt amp, BAF3 HER2 WT, BAF3 HER2 YVMA and BAF3 EGF dep. The IC_{50} values that inhibits cell proliferation are 6 nM, 33 nM, >5000 nM, 1 nM, 16 nM, and 1540 nM, respectively[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. WHO Drug Informat ion - World Health Organization (WHO).

[2]. Wilding Birgit, et al. Synthesis of diazino-pyrimidines as anticancer agents: World Intellectual Property Organization, WO2021213800. 2021-10-28.

[3]. Li S, et al. Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer. Cancers (Basel). 2023 May 24;15(11):2899.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA